Study of Anlotinib in Patients With Primary Malignant Bone Tumors
To evaluate the safety and efficacy of patients with recurrent and metastatic bone tumors.
Neoplasm of Bone
DRUG: Anlotinib
Progress free survival (PFS), From random grouping to the objective progression or death of a tumor, through study completion, an average of 6 month
Overall Survival (OS), The time in which the group begins to cause death for any reason, through study completion, an average of 10 month
To evaluate the safety and efficacy of patients with recurrent and metastatic bone tumors.